156 related articles for article (PubMed ID: 18198826)
1. Emerging opportunities for antipsychotic drug discovery in the postgenomic era.
Marino MJ; Knutsen LJ; Williams M
J Med Chem; 2008 Mar; 51(5):1077-107. PubMed ID: 18198826
[No Abstract] [Full Text] [Related]
2. Use of biomarkers in the discovery of novel anti-schizophrenia drugs.
Mikkelsen JD; Thomsen MS; Hansen HH; Lichota J
Drug Discov Today; 2010 Feb; 15(3-4):137-41. PubMed ID: 20036755
[TBL] [Abstract][Full Text] [Related]
3. Genome-based drug discovery: prioritizing disease-susceptibility/disease-associated genes as novel drug targets for schizophrenia.
Williams M
Curr Opin Investig Drugs; 2003 Jan; 4(1):31-6. PubMed ID: 12625025
[TBL] [Abstract][Full Text] [Related]
4. Commentary: genome-based CNS drug discovery: D-amino acid oxidase (DAAO) as a novel target for antipsychotic medications: progress and challenges.
Williams M
Biochem Pharmacol; 2009 Dec; 78(11):1360-5. PubMed ID: 19591808
[TBL] [Abstract][Full Text] [Related]
5. Preclinical epigenetic models for screening epigenetic drugs for schizophrenia.
Peedicayil J
J Pharmacol Toxicol Methods; 2016; 77():1-5. PubMed ID: 26370661
[TBL] [Abstract][Full Text] [Related]
6. Novel consortium to address shortfall in innovative medicines for psychiatric disorders.
Hughes B
Nat Rev Drug Discov; 2009 Jul; 8(7):523-4. PubMed ID: 19568273
[No Abstract] [Full Text] [Related]
7. Investigation of the expression of genes affecting cytomatrix active zone function in the amygdala in schizophrenia: effects of antipsychotic drugs.
Weidenhofer J; Scott RJ; Tooney PA
J Psychiatr Res; 2009 Jan; 43(3):282-90. PubMed ID: 18490030
[TBL] [Abstract][Full Text] [Related]
8. The impact of pharmacogenetics on the development and use of antipsychotic drugs.
Reynolds GP
Drug Discov Today; 2007 Nov; 12(21-22):953-9. PubMed ID: 17993414
[TBL] [Abstract][Full Text] [Related]
9. Metabotropic glutamate receptor 5 in schizophrenia: emerging evidence for the development of antipsychotic drugs.
Newell KA
Future Med Chem; 2013 Sep; 5(13):1471-4. PubMed ID: 24024939
[No Abstract] [Full Text] [Related]
10. Behavioral animal models of antipsychotic drug actions.
Peleg-Raibstein D; Feldon J; Meyer U
Handb Exp Pharmacol; 2012; (212):361-406. PubMed ID: 23129339
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic implications of neurobiological models of schizophrenia.
Goff DC
Harv Rev Psychiatry; 2005; 13(6):352-9. PubMed ID: 16373329
[TBL] [Abstract][Full Text] [Related]
12. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling.
Guidotti A; Dong E; Kundakovic M; Satta R; Grayson DR; Costa E
Trends Pharmacol Sci; 2009 Feb; 30(2):55-60. PubMed ID: 19110320
[TBL] [Abstract][Full Text] [Related]
13. The chakragati mouse: a mouse model for rapid in vivo screening of antipsychotic drug candidates.
Dawe GS; Ratty AK
Biotechnol J; 2007 Nov; 2(11):1344-52. PubMed ID: 17886239
[TBL] [Abstract][Full Text] [Related]
14. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder.
Gogos JA
Int Rev Neurobiol; 2007; 78():397-422. PubMed ID: 17349868
[TBL] [Abstract][Full Text] [Related]
15. Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back.
Bosia M; Pigoni A; Cavallaro R
Expert Opin Drug Discov; 2015 Feb; 10(2):125-39. PubMed ID: 25345474
[TBL] [Abstract][Full Text] [Related]
16. Genome-wide expression analysis of peripheral blood identifies candidate biomarkers for schizophrenia.
Kuzman MR; Medved V; Terzic J; Krainc D
J Psychiatr Res; 2009 Sep; 43(13):1073-7. PubMed ID: 19358997
[TBL] [Abstract][Full Text] [Related]
17. Schizophrenia risk genes: Implications for future drug development and discovery.
O'Connell G; Lawrie SM; McIntosh AM; Hall J
Biochem Pharmacol; 2011 Jun; 81(12):1367-73. PubMed ID: 21093417
[TBL] [Abstract][Full Text] [Related]
18. Gene expression of peripheral blood lymphocytes may discriminate patients with schizophrenia from controls.
Maschietto M; Silva AR; Puga RD; Lima L; Pereira CB; Nakano EY; Mello B; Gama CS; Belmonte-de-Abreu P; Carraro DM; Palha JA; Brentani H
Psychiatry Res; 2012 Dec; 200(2-3):1018-21. PubMed ID: 22633013
[TBL] [Abstract][Full Text] [Related]
19. Pathway-based association analysis of genome-wide screening data suggest that genes associated with the gamma-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia.
Inada T; Koga M; Ishiguro H; Horiuchi Y; Syu A; Yoshio T; Takahashi N; Ozaki N; Arinami T
Pharmacogenet Genomics; 2008 Apr; 18(4):317-23. PubMed ID: 18334916
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic drug actions on gene modulation and signaling mechanisms.
Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
